Myovant Sciences Ltd. (MYOV) EPS Estimated At $-0.77

June 12, 2018 - By Winifred Garcia

Analysts expect Myovant Sciences Ltd. (NYSE:MYOV) to report $-0.77 EPS on June, 13.After having $-0.70 EPS previously, Myovant Sciences Ltd.’s analysts see 10.00 % EPS growth. The stock decreased 0.50% or $0.11 during the last trading session, reaching $21.88. About 90,177 shares traded. Myovant Sciences Ltd. (NYSE:MYOV) has risen 73.54% since June 12, 2017 and is uptrending. It has outperformed by 60.97% the S&P500.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company has market cap of $1.42 billion. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It currently has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: